An ambitious GV-backed gene editing upstart re-emerges as a one-drug kidney company
In September 2019, Trucode Gene Repair launched, after two-plus years of early development, with $34 million from GV and Kleiner Perkins and ambitious plans to take on the raft of CRISPR companies with a new form of gene editing.
Those plans, though, would only last a few months. By February, company leadership was already pivoting, filing a trademark and domain name for a new company, called Vera Therapeutics. On Monday, they completed the switch, “launching” with an $80 million Series C round led by Abingworth and plans to focus their efforts on atacicept, a 20-year-old molecule now in development for kidney disease.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 112,900+ biopharma pros reading Endpoints daily — and it's free.